The Tactical Strategy, Readiness, Epidemiology and Reaction to Potential Treatments for the Possibly Lethal Ebola Virus: A Review

Over the preceding 38 years, a few outbreaks have been brought on by the Ebola virus, which produces the Ebola illness. No specific treatment has been approved for EVD. Problem management and supportive care are the cornerstones of treatment. Effective outbreak control requires a multidisciplinary team effort that includes case care, infection prevention and control protocols, contact tracing and surveillance, a high-quality laboratory service, dignified and safe funerals, and social and community mobilization. The 2014 Ebola outbreak started in Africa and swiftly spread to other continents before turning into a pandemic. The illness gained international interest because to its relatively peculiar design, lethality and contagiousness, difficulty in containing its spread, and absence of a reliable treatment. Two medications have received FDA approval to treat EVD. Ebanga is a single monoclonal antibody, whereas Inmazeb is a mixture of three monoclonal antibodies. Individuals utilizing any of the two FDA-approved treatments had a significantly greater overall survival rate. In this article, the known history of the Ebola virus, its mode of infection, epidemiology, lifecycle, and possible treatments are briefly reviewed.